Disarm Therapeutics Announces First Subject Enrolled in EPIPHANY Natural History Study of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
EPIPHANY study aims to characterize CIPN disease progression and associated biomarkers to guide future therapeutic development of SARM1 inhibitors CAMBRIDGE,…